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SOX9-regulated cell plasticity in 
colorectal metastasis is attenuated 
by rapamycin
Estefania Carrasco-Garcia1, Lidia Lopez1, Paula Aldaz1, Sara Arevalo1, Juncal Aldaregia1, 
Larraitz Egaña1, Luis Bujanda2, Martin Cheung3, Nicolas Sampron1, Idoia Garcia1,4 & 
Ander Matheu1,4
The cancer stem cell (CSC) hypothesis proposes a hierarchical organization of tumors, in which stem-
like cells sustain tumors and drive metastasis. The molecular mechanisms underlying the acquisition 
of CSCs and metastatic traits are not well understood. SOX9 is a transcription factor linked to stem cell 
maintenance and commonly overexpressed in solid cancers including colorectal cancer. In this study, we 
show that SOX9 levels are higher in metastatic (SW620) than in primary colorectal cancer cells (SW480) 
derived from the same patient. This elevated expression correlated with enhanced self-renewal activity. 
By gain and loss-of-function studies in SW480 and SW620 cells respectively, we reveal that SOX9 levels 
modulate tumorsphere formation and self-renewal ability in vitro and tumor initiation in vivo. Moreover, 
SOX9 regulates migration and invasion and triggers the transition between epithelial and mesenchymal 
states. These activities are partially dependent on SOX9 post-transcriptional modifications. 
Importantly, treatment with rapamycin inhibits self-renewal and tumor growth in a SOX9-dependent 
manner. These results identify a functional role for SOX9 in regulating colorectal cancer cell plasticity 
and metastasis, and provide a strong rationale for a rapamycin-based therapeutic strategy.
Cancers display a high degree of heterogeneity between individual patients but also between cancer cells within 
the same tumor. Both types of heterogeneity affect clinical practice. During the last decade, it has been demon-
strated that there is a population of cancer cells with stem-like properties, so-called cancer stem cells (CSCs), in 
several types of malignancies. CSCs are defined by their abilities to self-renew and generate differentiated prog-
eny. These characteristics enable them to be the root of malignancies and to play a major role in tumor initiation 
and recurrence, therapy resistance and metastasis1.
Colorectal adenocarcinoma is the second most commonly diagnosed type of cancer and constitutes the second 
leading cause of cancer-related mortality worldwide, causing nearly 700,000 deaths per year2. Colorectal cancer 
occurs sporadically in the majority of cases, being due to inherited mutations in less than 10% of patients. In most 
patients, death is not caused by the primary tumor, but rather by its metastasis in other organs and associated 
complications. Indeed, patients are generally diagnosed at an advanced stage, wherein the 5-year survival rate is 
only 11.7%2.
Ten years ago, various research groups demonstrated the existence of colorectal cancer stem cells (CR-CSCs), 
and revealed these cells to be responsible for treatment resistance3. More recently, it has been identified that 
CR-CSCs have a role as drivers of the metastatic progression of colorectal cancer4. Moreover, the expression of 
the CD44v6 variant of CD44 or CD110 was shown to serve as a biomarker for this CR-CSC pool of colorectal 
metastasis drivers5,6. These studies started to unravel the mechanisms involved in the regulation of CR-CSCs 
associated with metastasis and showed that plasticity between CR-CSCs and non-CR-CSCs occurs at advanced 
stages of tumor progression.
The transcription factor Sex-determining region Y (SRY)-box 9 (SOX9) plays a crucial role in stem cell main-
tenance and lineage commitment during embryonic development and also in adult tissue homeostasis. In the 
intestinal epithelium, lineage tracing and loss of function mouse models identified that Sox9 is a key regulator of 
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tissue homeostasis, regeneration and tumor initiation, through its functions in stem/progenitor cell maintenance 
and Paneth cell differentiation7–11. These activities arise acting as an effector and at the same time regulator of Wnt 
signaling10, a pathway whose activation is sufficient to initiate colorectal tumors, that is relevant for the mainte-
nance of CR-CSCs12. Moreover, it is the most frequently aberrantly activated pathway in colorectal cancer13.
There is growing evidence of the impact of SOX9 in human malignancies14–17. In particular, several studies 
have revealed that SOX9 is commonly overexpressed in colorectal cancers18–23, even in cases where the gene is 
mutated, event which happens in around 5–10% of cases13,24. Clinico-pathologically, high SOX9 expression corre-
lates with tumor progression and advanced tumor stage18 and has been associated with lower overall patient sur-
vival20,21. Functional studies have supported the view that SOX9 plays a pro-oncogenic role in primary colorectal 
cancer cells18,21, but under some circumstances it behaves as a tumor suppressor25,26. The role of SOX9 in the 
regulation of CR-CSCs has not been previously explored. In this work, we found that SOX9 is sufficient and nec-
essary for the acquisition and maintenance of CR-CSC and metastatic traits, properties linked to transcriptional 
and post-transcriptional regulation. Finally, we reveal that SOX9-mediated self-renewal and growth is impaired 
by the mTOR inhibitor rapamycin.
Results and Discussion
High levels of SOX9 correlate in CR-CSCs and metastatic cells. SW480 and SW620 cell lines were 
derived from a primary colorectal adenocarcinoma and its lymph node metastasis, respectively27. We started by 
characterizing the expression of CR-CSC markers3, finding that metastatic SW620 cells had higher levels of BMI1, 
CD133 and SOX9 than SW480 primary cells (Fig. 1A). These differences were markedly strong in the case of the 
last two genes. When SOX9 levels were compared with CRC human samples and matched adjacent colon tissue, 
we found SOX9 expression significantly increased in CRC tissues (p < 0.05), with levels in SW620 being between 
the most highly expressed cancer tissues, whereas in SW480 were near the lowest cases (Fig. 1B). Therefore, the 
level of expression of SOX9 in SW480 and SW620 cell lines is within the range of overexpression observed in 
human colorectal samples, suggesting that their levels are of biological relevance. SOX9 protein levels were also 
strikingly elevated in SW620 cells as well as phosphorylated SOX9 at serine 181 (Fig. 1C). This site is known to 
stimulate SOX9 transcriptional and DNA-binding activity28, indicating that SOX9 upregulation in metastatic 
cells is associated with transcriptional and post-transcriptional modifications. In clinical samples, SOX9 expres-
sion is higher in liver metastasis than matched primary colorectal cancers, where it is part of an aggressive stem 
Figure 1. High levels of SOX9 correlate with CR-CSCs. (A) Higher expression of stem cell markers in 
SW620 than in SW480 cells (n ≥ 3). (B) SOX9 mRNA expression relative to GAPDH in normal and tumoral 
colonic paired human samples and in SW480 and SW620 cell lines. (C) Higher SOX9 protein expression 
and phospho-SOX9 (S181) in SW620 cells than in SW480 cells. (D) Number of tumorspheres derived from 
SW480 and SW620 cells (n = 6). (E) SOX9 and BMI1 protein expression in tumorspheres and in parental 
SW480 and SW620 cells (n = 3). (F) Stem cell marker mRNA expression levels in tumorspheres relative to the 
corresponding parental cells (n ≥ 3).
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cell signature together with ASCL2, LGR5, EPHB3 and ETS229. Hence, our molecular identification of SOX9 is 
consistent with the clinical data, and together they show that SOX9 exhibits a dynamic expression in colorectal 
cancer, with high levels of SOX9 being associated with CR-CSCs and metastasis.
Next, we observed that the metastatic cells exhibited greater capacity to form tumorspheres (primary) than 
SW480 cells (26.6 in SW620 vs. 6.7 in SW480). Moreover, the ability for self-renewal, measured in terms of the 
number of secondary tumorspheres, was also much higher in SW620 cells (Fig. 1D). In agreement with the 
enrichment in the CR-CSC pool, we detected elevated expression of CD133, CD44 and BMI1, as well as SOX9, 
in tumorspheres formed from both cell lines (Fig. 1E,F). The above information, together with the evidence that 
both cell lines belong to the stem-like subtype showing high Wnt activity30, postulates SW480 and SW620 as 
suitable models to study the role of SOX9 in cellular plasticity and metastasis.
SOX9 overexpression provides stemness properties to colorectal cancer cells. To determine 
whether SOX9 activity is involved in the plasticity between non-CR-CSCs and CR-CSCs, we used a lentiviral 
vector harboring a plasmid with the SOX9 coding sequence to produce SOX9-overexpressing SW480 cells, and 
compared their functional properties to control empty-vector transduced cells. Western blotting revealed the 
overexpression of SOX9 in SW480 cells (Fig. 2A). Importantly, the ability to form tumorspheres was markedly dif-
ferent between control and SOX9 overexpressing cells. Indeed, cells with SOX9 overexpression generated 4-fold 
greater number of primary tumorspheres and 2.5-fold higher secondary tumorsphere formation (Fig. 2B). Next, 
we determined the effect of SOX9 overexpression on tumor initiation, a distinctive feature of CSCs1. Notably, by 
Figure 2. SOX9 overexpression provides self-renewal ability. (A) Representative immunoblots of SOX9 and 
BMI1 in SW480 cells transduced with SOX9 (SOX9) or empty vector (control) (n = 3). (B) Number of primary 
and secondary tumorspheres in control and SOX9 overexpressing SW480 cells (n ≥ 3). (C) Tumor initiation 
ability of indicated genotypes. Frequency of tumors formed in immunocompromised mice after subcutaneous 
injection of 1·106 cells. (D) Number of tumorspheres formed in control (− ), Sox9S64A,S181A and WT Sox9 SW480 
transduced cells (n = 3).
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10 days, all immunodeficient Foxn1nu/Foxn1nu mice inoculated with SOX9 overexpressing cells had developed 
tumors, compared to just over half (58%) of tumors derived from control cells (Fig. 2C). These results indicate 
that SOX9 promotes the acquisition of CR-CSC characteristics, both in vitro and also in vivo.
Given the differences observed in phosphorylated SOX9 between primary and metastatic cells, we wondered 
whether this activity might play a role in the gain of stemness. For this, we transduced SW480 cells with a con-
struct containing point mutations at S64 and S181 phosphorylation sites (Sox9S64A,S181A) or WT-Sox931 and com-
pared them to non-infected cells. We found that Sox9S64A,S181A cells formed fewer tumorspheres (0.65 fold) than 
WT-Sox9 and slightly more than controls (Fig. 2D). Another study has recently found that SLUG prevents SOX9 
ubiquitin-mediated proteasomal degradation, thereby controlling its stability and maintaining lung CSC activity32. 
To our knowledge, these studies have provided the first proofs of a role for SOX9 post-translational modifications 
associated with cancer phenotypes.
Since cancer cell motility and consequent invasion of the basement membrane have been associated with the 
gain of CSC properties and an epithelial mesenchymal transition (EMT) program33, we investigated the effect 
of ectopic SOX9 overexpression on these phenotypes. Stable overexpression of SOX9 resulted in a significant 
increase in the migratory potential of SW480 cells (Fig. 3A). Collagen invasion assays showed that high levels of 
SOX9 also enhanced their invasive potential (Fig. 3B). Moreover, migration ability (Fig. 3C) and invasive poten-
tial (Fig. 3D) were impaired in Sox9S64A,S181A cells, indicating that SOX9 phosphorylation is necessary, at least in 
part, for these processes. Next, we measured the expression of several EMT markers and detected a reduction in 
the expression of the epithelial adhesion protein E-Cadherin (Fig. 3E). In addition, SOX9 overexpression pro-
voked a robust induction of the mesenchymal marker Vimentin (Fig. 3E,F), which was reduced in cells lacking 
the phosphorylation sites (Fig. 3G). A previous study found that ectopic SOX9 induced an epithelial mesenchy-
mal transition (EMT) and led to the formation of more metastasis in vivo in an additional primary colorectal cell 
line21. Hence, high levels of SOX9 confer motility, invasive properties and a mesenchymal phenotype to primary 
colorectal carcinoma cells, all of them important features for the translocation of a cancer cell from the primary 
tumor to a distant tissue in metastasis.
At a molecular level, we have previously described that Sox9 modulates proliferation directly regulating 
Bmi118, a stem cell marker which genetic or pharmacologic inhibition irreversibly impairs CR-CSC activity34. 
Since we observed higher levels of both of them associated to CR-CSCs population (Fig. 1E), and in clinical sam-
ples18, we reasoned that BMI1 may be involved in SOX9-mediated colorectal cancer cell plasticity. In agreement 
with our hypothesis, the expression of BMI1 was higher in SOX9 overexpressing SW480 cells (Fig. 2A). In con-
trast, SW620 SOX9 silencing cells displayed BMI1 downregulation (Fig. 4A). ChIP-seq experiments revealed that 
SOX9 binds to the promoter of BMI1 in colorectal cells35, supporting that this regulation is direct. Overall, these 
data indicate that SOX9 modulates colorectal cancer cell plasticity regulating the dynamics of BMI1 and postulate 
SOX9-BMI1 as a critical axis for maintaining CR-CSCs activity and colorectal cancer pathobiology.
SOX9 is necessary for CR-CSCs maintenance. Having demonstrated that SOX9 promotes the acquisi-
tion of self-renewal and metastatic traits in primary colorectal carcinoma cells, we next determined its function 
in metastatic cells. For this, we knocked down SOX9 in SW620 cells using a specific short hairpin RNA (shSOX9). 
Quantitative real-time PCR and Western blotting demonstrated the silencing of the endogenous expression of 
SOX9 by shSOX9 (Fig. 4A,B). Strikingly, SOX9 downregulation resulted in a significant decline in the formation 
of both primary and secondary tumorspheres relative to that in SW620 control cells (Fig. 4C). Therefore, SOX9 
silencing abrogates the self-renewal ability of colon metastatic cells in vitro.
To corroborate the functional need of SOX9 for CR-CSC maintenance, we moved onto in vivo experiments. 
The ability to initiate tumors was severely impaired in SOX9-silenced cells relative to control cells. Specifically, 
41% of injections with shSOX9 cells developed tumors, while tumors were generated in all mice injected with con-
trol cells (Fig. 4D). Similarly, only 11% of inoculations developed tumors when injected with an additional short 
hairpin targeting a different SOX9 sequence (shSOX9-2) (Fig. 4D). Furthermore, tumors originating from shSOX9 
and shSOX9-2 cells grew more slowly than those from control cells (Fig. 4E,F). Strikingly, the impaired tumori-
genic activity of SOX9 knockdown cells (Fig. 4G) was further corroborated in vivo by reduced cell proliferation in 
the tumors. shSOX9 derived xenografts displayed lower number of Ki67 positive cells than tumors derived from 
control cells (p = 0.00049) (Fig. 4G,H). Together, these results show that the expression of SOX9 acts as a pleio-
tropic regulator maintaining self-renewal but also governing the proliferative capacity of colorectal cancer cells.
Next, we studied whether SOX9-mediated loss of stemness properties could affect phenotypes necessary for 
metastatic colonization in distant organs36. Thus, the invasive potential of metastatic cells in vitro was impaired 
as a consequence of SOX9 silencing (Fig. 5A). Moreover, immunofluorescence and Western blot analysis 
revealed that the levels of the mesenchymal markers Vimentin and N-Cadherin were lower in SW620 cells in 
the absence of SOX9 in vitro (Fig. 5B,C). These results were further validated in tumors originated from shSOX9 
cells (Fig. 5D). In line with these findings, genome-wide chromatin immunoprecipitation with DNA sequencing 
ChIP-seq analysis identified genes involved in EMT and quiescence as targets of SOX9 in colorectal cancer cells35. 
In summary, our results demonstrate that SOX9 activity is required for retaining metastatic CR-CSC functional 
properties.
SOX9 mediates rapamycin anti-tumorigenic effect. In CRC SOX9 overexpression is a strong predictor 
of shorter survival in 5-FU-treated patients and enhanced vascular invasion in biopsies22, whereas intestine stem 
cells expressing high levels of Sox9 are more resistant to irradiation in mice37. Since activation of CR-CSC sig-
naling is central to acquired resistance to therapy in colorectal cancer, our results suggest that pharmacological 
inhibition of SOX9 might be a novel therapeutic approach for this type of cancer.
www.nature.com/scientificreports/
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It has been shown that rapamycin inhibits the early stages of colorectal tumorigenesis, concomitantly with 
decreasing Sox9 in the Apcfl/fl mouse model38. Similarly, we have recently identified that rapamycin impairs gli-
oma stem cell activity through silencing of SOX2 and SOX9 expression39. Given that the mammalian target of 
rapamycin (mTOR) is frequently activated in human colorectal cancers, and its natural inhibitor rapamycin and 
rapalogs are promising antitumor agents, whose efficacy is currently being tested in clinical trials with promis-
ing results40, we explored a potential relationship between the mTOR pathway and SOX9 in human colorectal 
cells. We observed that, in parallel to SOX9, the endogenous levels of phosphorylated S6 Ribosomal protein, 
downstream target and likely physiological effector of the mTOR pathway, were higher in SW620 than in SW480 
cells (Fig. 6A). Next, we sought to establish whether rapamycin would be able to regulate metastatic cell activity 
Figure 3. SOX9 contributes to gain of metastatic traits in CRC cells. (A) Representative image and 
quantification of non-filled area in wound healing assays of SW480 control and SOX9 overexpressing cells 
(n = 4). (B) Representative images and quantification of transwell invasion for the indicated genotypes (n ≥ 3). 
(C) Representative images and quantification of transwell migration of SW480 control (− ) compared to cells 
transduced with Sox9S64A,S181A or a WT form of SOX9 (WT-Sox9) (n = 2). (D) Quantification of transwell  
in vitro invasion for the indicated conditions (n = 2). (E) Representative images of immunofluorescence studies 
of E-Cadherin and Vimentin in control and SOX9 overexpressing SW480 cells (n ≥ 2). (F) Representative 
Western blot of Vimentin in the indicated genotypes (n = 2). (G) Vimentin expression detected by 
immunofluorescence in SW480 cells transduced with the wt (WT Sox9) or the Sox9S64A,S181A mutant form of 
SOX9 (n = 2).
www.nature.com/scientificreports/
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through SOX9 activity. To answer this question, we first treated SW480 and SW620 cells with increasing concen-
trations of rapamycin (0.1, 10 and 100 nM) or vehicle (DMSO). SOX9 levels were not affected after cells cultured 
with the indicated concentrations of rapamycin (Fig. 6A). Given that the highest concentrations decreased the 
expression of SOX9 in glioma cells39, the effect of this agent on SOX9 expression seems to be context depend-
ent. On the contrary, 10 and 100 nM concentrations of rapamycin decreased phosphorylated S6 more strongly 
in SW620 than in SW480 cells (Fig. 6A). This evidence supports the idea of enhanced impairment of mTOR 
signalling pathway in the metastatic cells. Moreover, we found that 10 nM of rapamycin was sufficient to cause a 
severe reduction in the formation of primary (66% decrease in rapamycin vs. vehicle treated) and secondary (90% 
reduction) tumorspheres in SW620 cells, without affecting that capacity in SW480 cells (Fig. 6B,C).
Next, we checked the response of CR-CSCs with modulated levels of SOX9 to rapamycin treatment. For this, 
we treated gain and loss of SOX9 expression SW480 and SW620 cells with rapamycin (10 nM) or vehicle and 
Figure 4. SOX9 silencing impairs self-renewal of SW620 cells. (A) Representative immunoblots of SOX9 and 
BMI1 protein expression in empty vector (pLKO) and shSOX9 SW620 cells (n ≥ 3). (B) SOX9 mRNA levels in 
shSOX9 SW620 relative to pLKO cells (n = 3). (C) Plot of the number of primary and secondary tumorspheres 
in the indicated conditions (n ≥ 5). (D) Tumor initiation ability of the indicated cellular genotypes. Frequency 
of tumors formed in immunocompromised mice after subcutaneous injection of 1·106 cells per injection.  
(E) Tumor volume calculated at the indicated time points in nude mice injected with pLKO or two independent 
shSOX9 constructs (shSOX9 and shSOX9-2) (1·106 cells per injection). (F) Representative image showing the 
generated tumors per genotype. (G) Immunohistochemistry of SOX9 and Ki67 staining in SW620 derived 
tumors from pLKO or shSOX9 conditions (n = 4). (H) Quantification of percentage of Ki67 positive cells in 
SW620 derived tumors from pLKO or shSOX9 conditions (n = 4).
www.nature.com/scientificreports/
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cultured them under CSC conditions. Strikingly, SOX9-induced tumorsphere formation and self-renewal in 
SW480 cells was markedly attenuated by the presence of a 10 nM dose of the mTOR inhibitor (Fig. 6D). In con-
trast, that low dose of rapamycin promoted a decrease of 66 and 90% in primary and secondary tumorspheres 
in SW620 control cells, whereas the decline was only of 32 and 18% respectively in shSOX9 cells (Fig. 6E). These 
observations confirm that SOX9 levels sensitize CR-CSCs to rapamycin treatment, an effect likely mediated by the 
impairment of the mTOR signaling pathway, rather than the decline in SOX9 levels themselves.
In order to validate the antitumor activity of rapamycin in cells with different SOX9 expression in vivo, we 
injected SW620 and SW480 cells subcutaneously in nude mice and treated animals with 5 mg/Kg of rapamycin 
twice a week. This treatment resulted in delayed tumor initiation and a significant decrease in tumor growth in 
SW620 cells (p < 0.01) compared to that observed with the vehicle control treatments (Fig. 7A–C). In contrast, 
the mTOR inhibitor did not affect tumor growth of SW480 cells (Fig. 7C). As shown in in vitro studies, phos-
phorylated S6 Ribosomal protein was markedly decreased whilst SOX9 showed similar expression in rapamycin 
compared to vehicle treated SW620 tumors (Fig. 7D). Finally, we also evaluated molecular markers for cell pro-
liferation and apoptosis by immunohistochemistry. The expression of Ki67 was exclusively reduced (p < 0.05) 
in tumors obtained from SW620 cells treated with rapamycin (Fig. 7E and data not shown), whereas immuno-
histochemical staining for the apoptosis marker, fragmented PARP-1, was increased by rapamycin treatment 
(p = 0.004) (Fig. 7E). Together, these results show that rapamycin treatment attenuates CSC characteristics in 
colorectal cancer cells in a SOX9 expression dependent manner.
Figure 5. SOX9 silencing impairs metastatic phenotypes of SW620 cells. (A) Transwell invasion in SW620 
shSOX9 cells relative to SW620 control cells analyzed 24 hours after seeding (n = 3). (B) Vimentin and 
N-Cadherin mesenchymal markers expression analyzed by immunofluorescence in SW620 pLKO and shSOX9 
cells (n ≥ 2). (C) Representative western blot of Vimentin and N-Cadherin in SW620 pLKO and shSOX9 cells 
(n ≥ 2). (D) Vimentin expression detected by immunohistochemistry in subcutaneous tumors generated by 
pLKO and shSOX9 cells (n = 4).
www.nature.com/scientificreports/
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There is considerable focus nowadays studying the impact of cancer cell plasticity and metastasis. It is hint 
towards a complex network concerning heterogeneous pools of cells, which might interact within them or 
dynamically switch their characteristics41. These activities may be regulated in response to intracellular stress 
or microenvironmental stimuli via not well established molecular mechanisms yet. Our data indicate that the 
dynamics of SOX9 expression regulate colorectal cancer cell plasticity in a cell-autonomous manner. SOX9 directs 
cancer cell self-renewal and proliferation programs, governing the transition between CR-CSCs and non-CSCs. 
These functions are important for metastatic spread (Fig. 7F). Importantly, SOX9 inhibition impairs self-renewal 
and invasive potential, indicating that it might be considered as a novel therapeutic target for advanced colorectal 
cancers. In relation to this, we reveal that SOX9 levels define the antitumor action of the mTOR inhibitor rapamy-
cin in colorectal cells, providing preclinical evidence to justify further research into therapeutic strategies based 
on this agent, using SOX9 levels as a biomarker for patient stratification.
Figure 6. High SOX9 levels sensitize colorectal cancer cells to rapamycin. (A) Representative immunoblot 
of phospho-S6 Ribosomal protein (Ser235/Ser236) (p-S6), SOX9 and β -actin protein expression in SW480 
and SW620 cells treated with the indicated concentrations of rapamycin for 24 hours (n = 2). (B) Number of 
primary tumorspheres in SW480 and SW620 cells treated with vehicle (− ) or rapamycin 10 nM (Rap) (n = 4). 
(C) Number of secondary tumorspheres derived from SW480 and SW620 primary tumorspheres treated with 
vehicle (− ) or rapamycin 10 nM (Rap) (n = 4). (D) Number of tumorspheres formed by control and SOX9 
overexpressing SW480 cells in the presence or absence of rapamycin 10 nM (Rap) (n = 3). (E) Number of 
tumorspheres formed by pLKO and shSOX9 SW620 cells in the presence or absence of rapamycin 10 nM (Rap) 
(n = 3).
www.nature.com/scientificreports/
9Scientific RepoRts | 6:32350 | DOI: 10.1038/srep32350
Materials and Methods
Patients and tumor samples. Human colorectal carcinoma samples were provided by the Basque Biobank 
for Research-OEHUN (http://www.biobancovasco.org). The methods and experimental protocols in human 
Figure 7. Rapamycin impairs tumor growth in SW620 metastatic cells. (A) Percentage of nude mice 
harbouring SW620 derived tumors at the indicated time points after intraperitoneal treatment with vehicle 
(− ) or rapamycin 5 mg/Kg (Rap) twice a week (n = 8). Log-rank test (*p ≤ 0.05) (B) Representation of tumor 
volume formed by SW620 cells in immunocompromised mice treated with vehicle (− ) or rapamycin 5 mg/Kg 
(Rap) (n = 8). (C) Representative image of tumors formed from SW620 and SW480 cells treated with vehicle 
(− ) or rapamycin 5 mg/Kg (Rap). (D) Representative images of Ki67, fragmented PARP-1, p-S6, and SOX9 
immunostaining in SW620 derived tumors in the indicated conditions (n = 4). (E) Quantification of percentage 
of Ki67 and fragmented PARP positive cells (n = 3). (F) Illustrative image of the role of SOX9 in CRC cell 
plasticity. The expression of SOX9 regulates stemness activity and EMT plasticity in CRC cells mediating the 
pro-metastatic abilities of migration and invasion. High SOX9 expressing cells exhibit enhanced CR-CSC 
properties subjacent to enhanced pro-metastatic abilities. The mTOR inhibitor rapamycin exerts an enhanced 
antitumoral and anti-metastatic effect on CRC cells expressing high SOX9 levels.
www.nature.com/scientificreports/
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samples were carried out in accordance with relevant guidelines, and all study participants signed informed con-
sent form. The study was approved by the ethic committee of Biodonostia Institute and Hospital Donostia.
Cell lines culture conditions. SW480 and SW620 cell lines were obtained from the ATCC (American Type 
Culture Collection) and cultured as adherent monolayers in DMEM medium (Invitrogen) supplemented with 10% 
fetal bovine serum. Tumorspheres were cultured in DMEM/F12 medium (Sigma) supplemented with 20 ng/mL 
of EGF and bFGF (Sigma) growth factors, in the presence of N2 and B27. For tumorspheres studies, 0.5·103 cells/well 
were seeded in non-treated 12-well flat bottom plates and fresh medium was added every 3 days. After 10 days, 
primary (1ry) tumorspheres were counted. Then, spheres were disaggregated with Accutase, seeded for secondary 
(2ry) tumorspheres and maintained for another 10 days in culture.
Viral infections. Lentiviral infections were performed as previously described42. For gene knockdown, cells 
were transduced with two independent constructs; shSOX9 (a gift from Dr. Bob Weinberg, Addgene plasmid 
#40644)43 and shSOX9-2 (Sigma TRCN0000342824). For SOX9 overexpression, we used the plasmid #36979 
from Addgene, a gift from Bob Weinberg43. Plasmids with point mutations in S64 and S181 (Sox9S64A,S181A) or WT 
forms of Sox9 were gifts from Dr. Cheung. Cells were infected for 6 hours with a multiplicity of infection of 10.
mRNA expression analysis. Total RNA was extracted with TRIzol (Life Technologies). Reverse transcrip-
tion was performed using a High-Capacity cDNA Archive Kit (Life Technologies). Quantitative real-time PCR 
was performed using Power SYBR® Green Master Mix (Thermo Scientific), in an ABI PRISM 7300 thermocycler 
(Applied Biosystems). Variations in RNA input were corrected using the expression of the GAPDH housekeeping 
gene. The Δ Δ CT method was used for relative quantification.
Western blot and immunofluorescence analysis. Immunoblot and immunofluorescence analysis were 
performed as previously described18. Primary antibodies used were: SOX9 (AB5535, Millipore), phospho-SOX9 
(ab59252, abcam), BMI1 (05-637, Millipore), E-cadherin (BD610181, BD Transduction Laboratories), Vimentin 
(M7020, DAKO), N-Cadherin (BD610920, BD Transduction Laboratories), phospho-S6 Ribosomal protein (Cell 
Signaling Technology® , #4858) and β -actin (AC-15, Sigma). For Western blot detection of primary antibodies, 
we used HRP-linked antibodies (Santa Cruz Biotechnology) and detection was performed by chemiluminescence 
using NOVEX ECL Chemi Substrate (ThermoFisher). For immunofluorescence, secondary antibodies conju-
gated with fluorochromes were used and nuclear DNA was stained with Hoechst 33342 (Sigma). Images were 
obtained at a 40x magnification.
Migration and invasion assays. For wound healing (scratch) assays, cells were seeded at a confluence of 
90% in 24-well flat-bottom plates and 12 hours later a linear artificial gap (scratch) was made in serum-deprived 
conditions for 48 hours. The non-filled area (i.e., not covered by cell migration) was quantified using Scion 
image software (Scion Corporation). Transwell cell migration was evaluated using 6.5-mm Transwell® chambers 
with 8.0-μ m pore polycarbonate membrane inserts (Corning #3422). Invasion assays were performed using the 
QCM™ Collagen Cell Invasion Assay (ECM551, Millipore). Invading cells were quantified 24 hours after the 
seeding.
In vivo carcinogenesis assays. For subcutaneous injection, SW480 and SW620 cells were harvested with 
trypsin/EDTA and resuspended in PBS. Cells (1·106) were injected subcutaneously into both flanks of Foxn1nu/
Foxn1nu nude mice (8 weeks old). Mice were examined twice a week and external calipers were used to meas-
ure tumor size at the indicated time points from which tumor volume was calculated according to the formula 
½(length × width2).
For rapamycin experiments, SW620 and SW480 cells were treated for 48 h with rapamycin 10 nM before sub-
cutaneous implantation (1·106 cells in PBS). Five days later, mice were injected intraperitoneally with rapamycin 
(5 mg/kg) or vehicle twice a week during the experiment. Tumor volume was estimated as described above.
Immunohistochemistry. Tumors generated in mice were dissected, fixed in 10% formalin for 48h and 
embedded in paraffin. 4 micrometer-thick sections were incubated with primary antibodies (SOX9, AB5535 
(Millipore); Ki67, ab15580 (Abcam); Vimentin, M7020 (DAKO); phospho-S6 Ribosomal protein (Cell Signaling 
Technology® , #4858), and fragmented PARP-1, 32064 (Abcam) at 37 °C for 2 hours. The sections then were 
washed and incubated with MACH 3 Rabbit/Mouse Probe and MACH 3 HRP-Polymer (M3R531, Biocare 
Medical). Immunostaining was developed with 3,3′ Diaminobenzidine (DAB, SPR-DAB-060, Spring Bioscience).
Data analysis. Data are presented as mean values ± S.E.M. with the number of experiments (n) in paren-
thesis. Unless otherwise indicated, statistical significance (p-values) was calculated using the Student’s t test. 
Asterisks (*, **, and ***) indicate statistical significance (p < 0.05, p < 0.01, and p < 0.001, respectively).
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